Protagonist Therapeutics (PTGX) Accumulated Depreciation (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Accumulated Depreciation data on file, last reported at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation rose 19.91% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.7 million (up 19.91% YoY), and the FY2025 full-year result was $8.3 million, up 18.19% from the prior year.
• Accumulated Depreciation climbed to $8.7 million in Q1 2026, from $8.3 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $8.7 million in Q1 2026 to a low of $4.5 million in Q1 2022.
• A 5-year average of $6.5 million and a median of $6.5 million in 2024 frame the typical range for Accumulated Depreciation.
• Across the five-year window, Accumulated Depreciation rose 23.39% in 2022 and grew 12.43% in 2025, its largest moves.
• Tracing PTGX's Accumulated Depreciation over 5 years: stood at $5.3 million in 2022, then gained by 18.65% to $6.2 million in 2023, then advanced by 12.85% to $7.0 million in 2024, then grew by 18.19% to $8.3 million in 2025, then climbed by 4.89% to $8.7 million in 2026.
• Business Quant data shows PTGX's Accumulated Depreciation at $8.7 million in Q1 2026, $8.3 million in Q4 2025, and $7.9 million in Q3 2025.